Jean-Jaques Patard

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Pieter H.M. De Mulder a,y, Jean-Jaques Patard , Cezary Szczylik , Thomas Otto , Tim Eisen e Department of Medical Oncology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands b Service d’Urologie, CHU de Rennes, Rennes, France Department of Oncology, Military Institute of the Health Services, Warsaw, Poland Klinik für Urologie,(More)
Radical nephrectomy with total surgical removal remains the standard treatment for locally advanced renal cell carcinoma (RCC) in 2009. In the majority of cases such surgery is performed via an open route while it sometimes necessitates the involvement of a multidisciplinary team. Adjuvant and neo-adjuvant strategies using anti-angiogenic drugs are(More)
Renal cell carcinomas (RCC) are a heterogeneous group of tumors whose pathological aspects, molecular pathways and genetic bases differ. Study of RCC familial predisposition syndromes has enabled a better understanding of activated molecular pathways. Five signalling pathways have emerged: VHL/HIF/VEGF and mTOR pathways in clear cell RCC, C-MET and the(More)
For a long time, advanced or metastatic renal carcinoma has presented a difficult therapeutic challenge in oncology practice. Only a few years ago, treatment mainly involved immunotherapy, which frequently led to stalemate. In just a few years, new therapies targeting vascular endothelial growth factors and their receptors (VEGF-R): sorafenib, sunitinib and(More)
  • 1